DOMONIQUE WILSON: Open Payments
NPI 1124893151 · WASHINGTON, PA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$668 in 40 payments from 10 companies in 2025. Trend: 2023 $56 · 2024 $791 · 2025 $668
Food & beverage: $668
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 12 | $240 |
| ABBVIE INC. | 18 | $232 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 3 | $68 |
| Axsome Therapeutics, Inc. | 1 | $26 |
| Teva Pharmaceuticals USA, Inc. | 1 | $22 |
| Otsuka America Pharmaceutical, Inc. | 1 | $17 |
| Neurocrine BioSciences, Inc. | 1 | $17 |
| Lundbeck LLC | 1 | $16 |
| Supernus Pharmaceuticals, Inc. | 1 | $16 |
| Janssen Pharmaceuticals, Inc | 1 | $15 |
Products named: VRAYLAR, FANAPT, CAPLYTA, HETLIOZ, REXULTI, Auvelity, AUSTEDO XR, INGREZZA.
Industry payments across PA — which companies pay providers there.
